 Cholangitis, Sclerosing
"Cholangitis, Sclerosing" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Chronic inflammatory disease of the BILIARY TRACT. It is characterized by fibrosis and hardening of the intrahepatic and extrahepatic biliary ductal systems leading to bile duct strictures, CHOLESTASIS, and eventual BILIARY CIRRHOSIS.
| Descriptor ID |
D015209
|
| MeSH Number(s) |
C06.130.120.200.110
|
| Concept/Terms |
Cholangitis, Sclerosing- Cholangitis, Sclerosing
- Cholangitides, Sclerosing
- Sclerosing Cholangitides
- Sclerosing Cholangitis
- Cholangiitis, Sclerosing
- Cholangiitides, Sclerosing
- Sclerosing Cholangiitides
- Sclerosing Cholangiitis
Primary Sclerosing Cholangitis- Primary Sclerosing Cholangitis
- Cholangitides, Primary Sclerosing
- Primary Sclerosing Cholangitides
- Sclerosing Cholangitides, Primary
- Sclerosing Cholangitis, Primary
- Cholangitis, Primary Sclerosing
|
Below are MeSH descriptors whose meaning is more general than "Cholangitis, Sclerosing".
Below are MeSH descriptors whose meaning is more specific than "Cholangitis, Sclerosing".
This graph shows the total number of publications written about "Cholangitis, Sclerosing" by people in this website by year, and whether "Cholangitis, Sclerosing" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 | | 1997 | 1 | 0 | 1 | | 1998 | 1 | 1 | 2 | | 1999 | 2 | 0 | 2 | | 2000 | 2 | 0 | 2 | | 2003 | 2 | 0 | 2 | | 2004 | 1 | 1 | 2 | | 2006 | 1 | 1 | 2 | | 2007 | 1 | 0 | 1 | | 2008 | 3 | 0 | 3 | | 2009 | 1 | 0 | 1 | | 2010 | 1 | 1 | 2 | | 2012 | 0 | 1 | 1 | | 2013 | 2 | 0 | 2 | | 2014 | 1 | 0 | 1 | | 2016 | 2 | 1 | 3 | | 2017 | 3 | 0 | 3 | | 2018 | 1 | 0 | 1 | | 2020 | 1 | 0 | 1 | | 2021 | 4 | 0 | 4 | | 2022 | 3 | 0 | 3 | | 2023 | 4 | 0 | 4 | | 2024 | 2 | 1 | 3 | | 2025 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Cholangitis, Sclerosing" by people in Profiles.
-
Dean R, Yazdanfar M, Zepeda J, Levy C, Lammert C, Pratt D, Gordon SC, Forman L, Assis DN, McGirr A, McLaughlin M, Mukherjee S, Gungabissoon U, Bowlus CL. Treatment of pruritus in primary sclerosing cholangitis: Analysis of the consortium for autoimmune liver disease registry. Hepatol Commun. 2025 May 01; 9(5).
-
Shearn CT, Anderson AL, Devereaux MW, Koch SD, Larsen LD, Spencer LA, Orlicky DJ, Colgan SP, Steiner CA, Sokol RJ. Overexpression of TNFa in TNF?ARE+/- mice increases hepatic periportal inflammation and alters bile acid signaling in mice. Hepatol Commun. 2024 Dec 01; 8(12).
-
Kumar S, Lin S, Schold JD. Impact of graft type on outcomes following liver transplantation for primary sclerosing cholangitis. Hepatol Int. 2025 Feb; 19(1):244-255.
-
Ricciuto A, Liu K, El-Matary W, Amin M, Amir AZ, Aumar M, Auth M, Di Guglielmo MD, Druve Tavares Fagundes E, Rodrigues Ferreira A, Furuya KN, Gupta N, Guthery S, Horslen SP, Jensen K, Kamath BM, Kerkar N, Koot BGP, Laborda TJ, Lee CK, Loomes KM, Mack C, Martinez M, Montano-Loza A, Ovchinsky N, Papadopoulou A, Perito ER, Sathya P, Schwarz KB, Shah U, Shteyer E, Soufi N, Stevens JP, Taylor A, Tessier ME, Valentino P, Woynarowski M, Deneau M. Oral vancomycin is associated with improved inflammatory bowel disease clinical outcomes in primary sclerosing cholangitis-associated inflammatory bowel disease (PSC-IBD): A matched analysis from the Paediatric PSC Consortium. Aliment Pharmacol Ther. 2024 05; 59(10):1236-1247.
-
Yazdanfar M, Zepeda J, Dean R, Wu J, Levy C, Goldberg D, Lammert C, Prenner S, Reddy KR, Pratt D, Forman L, Assis DN, Lytvyak E, Montano-Loza AJ, Gordon SC, Carey EJ, Ahn J, Schlansky B, Korzenik J, Karagozian R, Hameed B, Chandna S, Yu L, Bowlus CL. African American race does not confer an increased risk of clinical events in patients with primary sclerosing cholangitis. Hepatol Commun. 2024 02 01; 8(2).
-
Bowlus CL, Eksteen B, Cheung AC, Thorburn D, Moylan CA, Pockros PJ, Forman LM, Dorenbaum A, Hirschfield GM, Kennedy C, Jaecklin T, McKibben A, Chien E, Baek M, Vig P, Levy C. Safety, tolerability, and efficacy of maralixibat in adults with primary sclerosing cholangitis: Open-label pilot study. Hepatol Commun. 2023 06 01; 7(6).
-
Bowlus CL, Arriv? L, Bergquist A, Deneau M, Forman L, Ilyas SI, Lunsford KE, Martinez M, Sapisochin G, Shroff R, Tabibian JH, Assis DN. Reply: Insurance should cover vancomycin for primary sclerosing cholangitis. Hepatology. 2023 06 01; 77(6):E176-E177.
-
Forman LM, Sapisochin G, Assis DN, Arriv? L, Bergquist A, Bowlus CL, Deneau M, Ilyas SI, Lunsford KE, Martinez M, Shroff R, Tabibian JH. Reply: Living donor liver transplantation for people with PSC. Hepatology. 2023 05 01; 77(5):E97-E98.
-
Shearn CT, Anderson AL, Miller CG, Noyd RC, Devereaux MW, Balasubramaniyan N, Orlicky DJ, Schmidt EE, Sokol RJ. Thioredoxin reductase 1 regulates hepatic inflammation and macrophage activation during acute cholestatic liver injury. Hepatol Commun. 2023 01 01; 7(1):e0020.
-
Bowlus CL, Arriv? L, Bergquist A, Deneau M, Forman L, Ilyas SI, Lunsford KE, Martinez M, Sapisochin G, Shroff R, Tabibian JH, Assis DN. AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma. Hepatology. 2023 02 01; 77(2):659-702.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|